Skip Navigation

Annals of Oncology 2006 17(Supplement 7):vii49-vii50; doi:10.1093/annonc/mdl950
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pignata, S.
Right arrow Articles by Iaffaioli, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pignata, S.
Right arrow Articles by Iaffaioli, R. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Medical treatment of resistant or recurrent epithelial ovarian cancer

S. Pignata1,*, C. Pisano1, M. Di Maio1, F. Iodice2, G. Casella2, G. Laurelli2, S. Greggi2 and R. V. Iaffaioli1

1 Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli; 2 Divisione di Ginecologia Oncologica, Istituto Nazionale Tumori, Napoli, Italy

* Correspondence to: Dr S. Pignata, Divisione di Oncologia Medica B, Istituto Nazionale Tumori, via M. Semmola, 80131 Napoli, Italy. Tel: +39-81-5903269; Fax: +39-81-5903822; E-mail: sandro.pignata{at}fondazionepascale.it

Epidemiologic analysis reveals that mortality rates from ovarian cancer are continuously decreasing due to the improvement of surgery and chemotherapy. However, overall, the prognosis of ovarian cancer patients is still unsatisfactory considering that only 30% of the patients are alive after 5 years. In fact, although surgery and first-line systemic chemotherapy induce complete and partial response in up to 80% of patients, with about a 25% pathological complete remission rate, recurrences occur in the majority of patients. Most of these patients are subject to repetitive treatment cycles that, although palliative in nature, are also able to prolong survival. Important results have been obtained, in particular in platinum sensitive recurrent disease where a platinum base chemotherapy is able to prolong progression-free survival and overall survival. Overall, our armamentarium for the treatment of progressive or recurrent ovarian cancer is significantly richer than in the past, and in many patients it is possible to achieve the objective to reach a chronic history of the disease.

Key words: ovarian cancer, chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Lassmann, Y. Shen, U. Jutting, P. Wiehle, A. Walch, G. Gitsch, A. Hasenburg, and M. Werner
Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy
Clin. Cancer Res., July 15, 2007; 13(14): 4083 - 4091.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.